Background: A web-based multicenter Korean Prostate Cancer Database (K-CaP) was established to provide urologists with information on Korean prostate cancer (PCa) patients treated with radical prostatectomy (RP). We utilized the K-CaP registry to identify pathological features and oncological outcomes of Korean PCa patients eligible for active surveillance (AS). Methods: The K-CaP registry consisted of 6415 patients who underwent RP from May 2001 to April 2013 at five institutions. Preoperative clinicopathological data were collected to identify patients who were eligible for at least one contemporary AS protocol. Patients who had received neoadjuvant androgen deprivation therapy or a 5α-reductase inhibitor, who had <10 total biopsy cores, or who had incomplete data were excluded. Biochemical recurrence (BCR) was defined as prostate-specific antigen (PSA) level ≥0.2 ng/ml following RP. Results: A total of 560 patients were identified, and the median follow-up period was 52.0 (interquartile range, 39.0-67.3) months. Pathologically insignificant PCa, defined as organ-confined disease with Gleason score ≤6 was observed in 314 (56.1%) patients. Pathological upgrading (Gleason score ≥7) and upstaging (≥pT3) were observed in 237 (42.3%) and 75 (13.4%) patients, respectively. Unfavorable disease (extracapsular extension, seminal vesicle invasion, or Gleason score ≥8) was observed in 85 (15.2%) patients. PSA density ≤0.2 ng/ml/cc and maximal single core involvement ≤20% were revealed as independent preoperative predictors of pathologically insignificant PCa. Conclusion: Contemporary Western AS protocols unreliably predict pathologically insignificant PCa in Korean men. Korean men may harbor more aggressive PCa features than Western men, and thus, a more stringent AS protocol is needed.
Introduction
Prostate-specific antigen (PSA) screening has revolutionized the early diagnosis and treatment of prostate cancer (PCa) (1) . In line with the era of PSA screening, there has been a downward risk and stage migration in PCa detection (2) . Radical prostatectomy (RP) is a curative treatment option for localized organ-confined PCa. However, it poses the risk of overtreatment and associated morbidities for a subset of patients with low-risk PCa who can be safely monitored without immediate treatment.
Active surveillance (AS), which was first introduced in the 1990s, has emerged as a feasible option for patients with low-risk PCa. Recent studies have reported an excellent 10-year disease-specific mortality rate of 3%, even with the most lenient contemporary protocol (3) . The adoption of an appropriate eligibility protocol for a certain population is critical to meet the needs of AS (4) . A number of prognostic models have been proposed to identify the subgroup of patients eligible for AS. However, their accuracy is limited, and validation has been performed with limited number of patients. Moreover, most contemporary AS protocols have been established based on the oncological outcomes of Western patients, and there is lack of evidence as to whether they could be safely adapted for Asian patients with low-risk PCa.
An exponential increase in investigations regarding the pathological features of PCa in Korean men has been observed because of the recent nationwide increase in RP cases. A racial difference in PCa features and outcomes has been reported, in which Korean men with clinically insignificant PCa have exhibited substantially higher rates of pathological upgrading and upstaging following RP compared with Western men (5-7). Accordingly, a consensus exists among Korean urologists that extensive monitoring for early detection of disease progression is required for patients on AS. However, as of yet, there have been no data on the clinical and oncological outcomes of PCa at a national level.
A web-based, multicenter Korean Prostate Cancer Database (K-CaP) was established in 2011 to provide urologists with information on Korean patients with PCa treated with RP. Our objective was to utilize the K-CaP registry to identify the pathological features and oncological outcomes of Korean PCa patients who are eligible for AS, and thereby to investigate the feasibility and safety of Western AS protocols.
Materials and methods

Study population
Clinicopathological data of the patients and their oncological outcomes were retrieved from the K-CaP registry. The K-CaP registry is an online, observational and automated data-entry system, consisting of 6415 patients who underwent RP between May 2001 and April 2013 at five high-volume institutions in Korea: Asan Medical Center, Samsung Medical Center, Seoul National University Bundang Hospital, Seoul St. Mary's Hospital and Yonsei University Severance Hospital. Details of the database have been previously reported (8) . For all patients, the decision for RP was made based on the physician's discretion and the patient's preference. Informed consent was not obtained from all study subjects owing to the retrospective nature of the K-CaP registry. However, the study was carried out in accordance with the principles of the Helsinki Declaration of 1964, as updated in 2008, and the collection of retrospective data was approved by the institutional ethics committee after review of the protocol and procedures employed (2016-0493-001).
Preoperative clinicopathological data were collected to identify patients who were eligible for at least one of the following contemporary published AS protocols ( Patients who received neoadjuvant androgen deprivation therapy or 5α-reductase inhibitors and those who had fewer than 10 total biopsy cores were excluded from analysis, as were men with incomplete follow-up data.
Assessments of clinicopathological variables
The multiparametric magnetic resonance imaging data of the enrolled patients were interpreted by radiologists at each participating hospital. Radiographic factors analyzed included tumor stage, extracapsular extension (ECE) and seminal vesicle (SV) invasion.
All pathological specimens were fixed, serially sectioned and processed according to the well-established protocols of each institution. Pathologic factors analyzed included prostatectomy Gleason score and tumor stage, tumor volume, lymphovascular and perineural invasions, ECE, SV invasion and surgical margin status.
Study endpoints
The primary endpoint was to identify the pathological features and oncological outcomes of Korean PCa patients who were eligible for AS. Clinical outcome measures included age, body mass index (BMI), preoperative serum PSA level, PSA density (PSAD), pathological Gleason score, pathological tumor stage, ECE, surgical margin status, SV invasion, tumor volume, pathological upstaging (≥pT3), upgrading (postoperative Gleason score ≥7), pathologically insignificant disease (organ-confined, Gleason score ≤6), unfavorable disease (ECE, SVI or Gleason score ≥8), and biochemical recurrence (BCR). BCR was defined as the first of 2 or more consecutive increases in PSA of > 0.2 ng/ml that occurred at least 3 months after surgery. 
Statistical analysis
Demographic characteristics were compared using descriptive statistics. Comparative tests, namely, the Mann-Whitney U test and the Fisher's exact test, were used to compare continuous and categorical variables. Variables that were considered potential predictors for multivariate modeling were selected using univariate analyses and the logistic regression model. Statistical analysis was performed using SPSS version 18 (SPSS Inc., Chicago, IL, USA) with statistical significance set at P < 0.05.
Results
Patient and tumor characteristics
The clinicopathological features of 560 patients who were eligible for at least one contemporary published AS protocol are presented in Table 2 . The distribution of the patients with respect to clinical and pathological features did not differ among institutions (data not shown).
Postoperative outcomes
Postoperative outcomes of the study cohort are presented in Table 3 . Pathological upgrading (Gleason score ≥7) and upstaging (≥pT3) were observed in 237 (42.3%) and 75 (13.4%) patients, respectively. Three hundred and fourteen (56.1%) patients exhibited organ-confined, Gleason score ≤6 disease, whereas 85 (15.2%) patients were found to harbor unfavorable disease. During the median follow-up period of 52.0 (IQR 39.0-67.3) months, BCRfree survival, cancer-specific survival and overall survival were 84.3%, 98.2% and 97.5%, respectively.
AS is recommended for patients with at least a 10-year life expectancy. With regard to the life expectancy in Korean men (9), we further analyzed pathological outcomes of patients stratified as older or younger than 75 years ( Table 4 ). The frequencies of upstaging, upgrading, and unfavorable disease were comparable between the two groups.
Preoperative predictors of pathologically insignificant disease
Preoperative predictors of pathologically insignificant disease are presented in Table 5 . Univariate logistic regression analysis identified PSA ≤10 ng/ml (OR = 1.438, 95% CI 0.995-2.077; P = 0.047), PSAD ≤0.2 ng/ml/cc (OR = 1.852, 95% CI 1.242-2.761; P = 0.002), and maximal single core involvement ≤20% (OR = 0.984, 95% CI 0.968-0.999; P = 0.042) as preoperative predictors. PSAD ≤0.2 ng/ml/cc (OR = 1.845, 95% CI 1.232-2.761; P = 0.003) and maximal single core involvement ≤20% (OR = 1.517, 95% CI 1.007-2.289; P = 0.046) were revealed to be independent preoperative predictors of organ-confined, Gleason score ≤6 disease.
Discussion
The majority of patients diagnosed with PCa actually harbor lowrisk tumors that can be safely monitored and do not require immediate treatment. A major challenge in PCa management is to find a balance between maximizing the number of patients who can avoid treatment, and at the same time, minimize the number of aggressive PCa cases that are missed. An appealing approach is AS, for which several institutions in North America and Europe have proposed protocols to distinguish low-risk PCa and confer long-term oncological safety (3). However, these protocols have been formulated based on the pathological outcomes of Western men, and currently there are no data on whether these protocols can be safely adapted for use in Asian men. Thus, we investigated the characteristics and outcomes of Korean patients with PCa.
Our results imply that Korean men harbor more aggressive PCa features than Western men, and raise the concern that contemporary Western AS protocols could prevent a substantial proportion of Korean patients with unfavorable disease from receiving a timely diagnosis. In a similar representative study on Western men, pathological and oncological outcomes were evaluated in 391 patients fulfilling any contemporary AS protocols, which were consistent with those used in our study (10) . In the same study, organ-confined Gleason score ≤6 disease was reported in 69.2% of patients, a prevalence that was higher than the 56.1% reported in our study. Moreover, the rates of ECE and pathological upgrading (Gleason score ≥7) were reported to be 4.1% and 27.8%, respectively, which were considerably lower than the rates of 12.9% and 42.3% that were observed in our study. Higher pathological stage and grade are associated with poorer survival following RP (11) . Compared with the 5-year BCRFS rate of 84.3% in our cohort, Western men exhibited a 5-year BCRFS rate of 90.9%, presumably resulting from the higher upstaging and grading rates (10, 12) . Nevertheless, this did not translate into differences in cancer-specific survival or overall survival.
The pathophysiology underlying racial disparity in PCa features is incompletely understood. An autopsy study in Japanese and Russian men found that 51% of the cancers in Japanese men had a Gleason score of >7, which was significantly higher than the rates of 23% in Russian men and 30% in US men (12, 13) . Several reports have suggested potential underlying mechanisms. PCa is a hormone-dependent cancer, and the role of testosterone is essential in the normal differentiation of the prostate epithelium (14) . When testosterone is insufficient, the prostate proliferation cycle is affected and exerts abnormal epithelial differentiation, resulting in poor differentiation (15) . The inhibition of 5-alpha-reductase lowers intraprostatic levels of dihydrotestosterone, and this relatively lower androgen environment induces the development of poorly differentiated PCa, namely, more aggressive tumors and higher Gleason grade cancers (16). Hoffman et al. evaluated serum testosterone levels in patients who underwent prostate biopsy, and reported that lower levels of testosterone were associated with more extensive disease, based on a higher percentage of positive biopsies and a higher prevalence of Gleason score ≥8 disease (15) . Asian men have lower levels of total serum testosterone and hormone-binding levels, reduced 5-alpha-reductase levels, and lower testosterone production than Western men;(17) thus, testosterone metabolism could be the main factor underlying the differences in PCa features between Western and Asian men.
The difference in body fat distribution between Western and Asian men is another possible explanation of our observations. Asian men, in general, have a lower BMI than Western men, and the average BMI is below 25 kg/m 2 in some Asian countries (18) .
Numerous studies have suggested biological mechanisms underlying the association between body fat distribution and PCa risk (19) . Potential mechanisms underlying our observation that Asian men harbor more aggressive PCa include increased levels of sex hormone-binding globulins, decreased serum levels of insulin-like growth factor 1, and altered expressions of estrogenic compounds (20, 21) . Estrogen receptors (ERs) α and β have opposite functions in the prostate by promoting or inhibiting cell proliferation and malignant transformation of prostate cells (22, 23) . Several lines of evidence suggest that obesity is linked to decreased ERα and increased ERβ expression (24) . ERα is involved in the growth of normal stromal cells and has been shown to be a mediator of premalignant lesions and carcinogenesis (25) . In contrast, ERβ is associated with anti-proliferative and anti-inflammatory activity in PCa cells by inactivating ERα. Several studies have found that obese men exhibit upregulated ERβ protein expression in the prostate, and suggested that the inhibition of estrogens with higher binding affinity for ERβ than for ERα may induce PCa carcinogenesis (22, 26) . Although the exact mechanisms are yet to be clarified, observations that obese men harbor lower-grade cancers and lower BCRFS supports the presumption that the protective role of ERβ signaling in PCa carcinogenesis is reduced in Asian men. Within multivariate models of predictors of organ-confined, Gleason score ≤6 disease incorporating detailed biopsy core data, PSAD was an independent predictor instead of PSA. This observation is consistent with previous studies in which PSAD significantly increased the predictive accuracy for pathological upgrading, even when accounting for PSA (27, 28) . A potential explanation is the effect of prostate volume. Patients with smaller prostates have higher rates of upgrading and more advanced disease compared with those with larger prostates (29) . While the biological mechanism underlying the association between Gleason score and prostate volume is yet to be elucidated, the higher rate of PSA-driven biopsies in patients with larger prostates is a possible explanation. Our results indicate that PSAD could be a valuable tool to identify patients harboring clinically insignificant disease among those who are eligible for contemporary AS protocols.
The present study has noteworthy limitations. First, patients included in the K-CaP registry may have been diagnosed and treated at a later stage than Western men, and therefore, the results may contain selection bias. Second, the relatively short follow-up period was insufficient to assess the overall survival of the cohorts. Third, pathologists from different institution were involved and a central pathology review was not performed. Fourth, a doubt remains whether our study participants indeed represent PCa features of Korean men as a whole. Nonetheless, our study has the strengths of a large overall number of PCa patients treated with RP retrieved from the K-CaP database, the largest existing multicenter registry representative of the Korean population. Finally, we were unable to provide a new AS protocol specific for the Korean population, because the total follow-up period was relatively short, and also, the number of events was limited to achieve a meaningful conclusion. Nonetheless, our results have implications for future studies involving genetic characterization of PCa risk according to ethnicity, and novel therapeutics targeted at testosterone metabolism.
Conclusions
Contemporary Western AS protocols unreliably predict pathologically insignificant PCa in Korean men. Our results imply that Korean men may harbor more aggressive PCa features than Western men, and thus, a more stringent AS protocol is needed. These differences should be taken into account when making treatment decisions in patients with low-risk PCa. Furthermore, comprehensive integration of high-volume Asian PCa data is warranted for the development of a more accurate and balanced AS protocol that is applicable to the Asian population.
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